Seeking Alpha

More on Gilead Sciences (GILD): Q3 beats across the board. Net earnings fell 8.9% Y/Y however,...

More on Gilead Sciences (GILD): Q3 beats across the board. Net earnings fell 8.9% Y/Y however, on higher R&D expenses to advance its liver disease and oncolodgy products. Overall product sales rose 14%, with sales of antiviral products, its dominant revenue stream, increasing 13%. HIV drugs Atripla and Truvada both saw sales gains of 9% and 8%, respectively. Royalty, contract and other revenue from collaborations were up 23% from the prior year. Shares +1.7% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|